Prevalence and early outcome of bronchiectasis as an atypical presentation in COVID-19 patients

Aliae A. R. Mohamed Hussein, Ahmad M. Shaddad, Maiada K. Hashem* and Maha Ahmed Okasha

Abstract
Introduction: Bronchiectasis was considered as an uncommon radiological feature of corona virus disease 2019 (COVID-19) infection. The clinical course and outcome of COVID-19 bronchiectasis overlap is still a point for research. The aim of this study was to evaluate the prevalence, course, and outcome of bronchiectasis as an atypical presentation of COVID-19 infection.

Methods: A cross-sectional study has been conducted from July 2021 to February 2022 and included 425 COVID-19 swab-positive patients who were examined by high resolution computed tomography of the chest during acute phase (4 weeks) of the infection.

Results: Fourteen (3.3%) patients newly developed bronchiectasis-de novo. Patients with de novo bronchiectasis had significantly higher cough score, frequency of colored sputum and mMRC score, respiratory distress ($p < 0.001$) and respiratory failure ($p = 0.02$) than patients with no bronchiectasis. They also had the higher frequency of ICU’s admission ($p = 0.02$), need to non-invasive ($p = 0.01$), and invasive mechanical ventilation ($p < 0.001$), duration of mechanical ventilation, ICU’s stay and overall hospital stay ($p < 0.001$). As for the outcome, death rate was also statistically significantly higher among those with De novo bronchiectasis than those without bronchiectasis ($p = 0.04$).

Conclusion: Bronchiectasis is an uncommon presentation among COVID-19 patients. However, bronchiectasis increases disease burden in COVID-19 patients. It may have a negative impact on the outcome.

Trial registration: ClinicalTrials.gov. NCT04910113. Registered June 2, 2021.

Keywords: COVID-19, Bronchiectasis, De novo, Prevalence, Outcome

Introduction
Since February 2020 World Health Organization (WHO) named the novel variant coronavirus that was detected from the bronchoalveolar lavage of some patients suffering from severe lower respiratory tract infection in Wuhan City, China, in December 2019 [1] as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). WHO called this infection Coronavirus Disease 2019 (COVID-19) which was declared on March 11th, 2020, as a global pandemic. On 18 April 2022, over 500 million confirmed cases and over 6.19 million deaths have been reported globally [2].

The typical chest CT appearance of COVID-19 pneumonia is bilateral peripheral ground-glass opacities (GGO), sometimes with areas of consolidation, with a prominent lower lung distribution [3, 4].

Bronchiectasis is a chronic lung condition, characterized clinically by dyspnea, productive cough, and recurrent respiratory infections, and radiologically by abnormal and permanent dilatation of the bronchi. The main radiological findings detected in chest CT of bronchiectasis are (1) internal diameter of a bronchus is wider...
than its adjacent pulmonary artery; (2) loss of bronchial tapering; and (3) extension of visualized dilated bronchi into the outer cortical lung areas [4].

One of the reported radiological findings in patients with COVID-19 infection was bronchiectasis. However, published studies lacked reporting the onset and evolution of bronchiectasis during the short term follow-up as well as long-term complications among those patients [5].

Traction bronchiectasis is a common variant of bronchiectasis which can be described as bronchial dilatation secondary to mechanical traction from adjacent pulmonary fibrosis. Pathogenesis was assumed to occur during severe COVID-19. In addition, lung injury secondary to mechanical ventilation due to severe infection could be added to this theory [6].

This study aims to evaluate the prevalence and pattern of bronchiectasis as an atypical presentation of COVID-19 infection and to assess the course and outcome of COVID-19 infection presented with bronchiectasis during the acute phase of the disease.

**Patients and methods**

A cross-sectional study has been conducted at Assiut University and Assiut Police Hospitals from July 2021 to February 2022. Patients who were enrolled in this study were either from patients admitted to the hospitals or those who went to the outpatient’s clinics. Diagnosis of COVID-19 infection among the participants was established according to the WHO and Egyptian Ministry of Health and Population (MOHP) guidelines [7, 8]. The cornerstone for diagnosis were RT-PCR and MSCT chest. Case detection was done using RT-PCR for the viral RNA by TaqMan™ 2019-nCoV Control Kit v1 (Cat. No. A47532) supplied by QIAGEN, Germany on the Applied Biosystem 7500 Fast RT PCR System, USA. All patients admitted during the study period in study hospitals with confirmed COVID-19 infection and met the inclusion criteria were included in this study.

The inclusion criteria were adult patients aged 18 years or older, of both genders who were diagnosed as COVID-19-positive by RT-PCR in Assiut University and Assiut Police hospitals during the study period who had chest CT scan examination during acute stage of the diseases. Children under 18 years old, patients who were not examined by CT scan of the chest and those who refused to participate in the study were excluded.

**Data collection**

All patients included in this study were subjected to detailed history and physical examination, relevant laboratory investigations such as complete blood picture, inflammatory markers, and arterial blood gases, as well as high-resolution CT chest.

Regarding the symptoms evaluation, dyspnea was assessed by modified medical research council (mMRC) score while cough was assessed by Cough Symptom Score (CSS) which is a simple a two-part questionnaire referring to daytime and night-time symptoms. Based on the frequency, intensity and influence of cough on daily activities and sleep, cough symptoms are scored from 0 to 5, with 0 indicating no cough and 5 indicating the most severe cough [9].

The computed tomography was performed using GE Optima 64 slices made in the USA. Patients were examined in supine position. The scanning extended superiorly from the thoracic inlet and ended by the diaphragm. No contrast media injection was used in either patient. All CT examinations were reviewed and reported by the attending radiologists who were blinded to the study. CT sections of all patients were examined for the presence and distribution of any of the following: ground-glass opacities (GGO), consolidation, multifocality, distribution (peripheral or diffuse), septal thickening, crazy paving, pulmonary nodules, pleural effusion, and mediastinal lymph nodes for the diagnosis of COVID-19 infection and assessment of its severity [3, 10]. They also were assessed for the presence of any increase in bronchial to adjacent pulmonary artery diameter ratio, loss of the bronchial tapering, and visualization of bronchi in the outer 1–2 cm of the lung fields for the diagnosis of bronchiectasis with evaluation of its anatomical distribution [11].

Based on the clinical and radiological evidence of bronchiectasis diagnosis patients were divided into three groups:

- Group I included COVID-19 patients without bronchiectasis.
- Group II included COVID-19 patients who newly developed bronchiectasis-de novo.
- Group III included COVID-19 patients with preexisting chronic bronchiectasis. Group III were then excluded from further statistical analysis in this study.

**Ethical considerations**

The study was approved by Assiut University, Faculty of Medicine ethical committee under (IRB no. 17101456). The singed informed consent form was a permanent part of the participants study records, and it was maintained in the same manner as other records. Patients’ identity and personal information were concealed, and each patient assigned for a code to insure privacy and confidentiality of the data. It was performed according to
the provisions of the Declaration of Helsinki. The study was also registered in clinicaltrials.gov under number (NCT04910113).

Statistical analysis
Data was collected and analyzed by using SPSS (Statistical Package for the Social Science, version 20, IBM, and Armonk, New York). The Shapiro test was used to determine compliance of the data to normal distribution. All quantitative data in the current study had abnormal distribution and compared with Mann-Whitney test. Nominal data were given as number (n) and percentage (%). Chi² test was implemented on such data. P value was considered significant if < 0.05.

Results
A total of 425 patients with confirmed COVID-19 infection were enrolled in the current study. Based on development of bronchiectasis, those patients were subdivided into the following groups:

- Group I: COVID-19 patients without bronchiectasis, 400 (94.1%) patients,
- Group II: COVID-19 patients who newly developed bronchiectasis- De novo, 14 (3.3%) patients, and
- Group III: COVID-19 patients with preexisting chronic bronchiectasis, 11 (2.6%) patients. Group III were then excluded from further statistical analysis in this study.

The flowchart of recruited cases is shown in (Fig. 1).

The mean age of the patients in the two groups were 52.62 ± 17.80 and 57.64 ± 10.96 years respectively and more than half of them were males with no statistically significant difference. Patients with de novo bronchiectasis had significantly higher frequency of COPD in comparison to those without bronchiectasis (42.9% vs. 6.5%; p < 0.001) (Table 1).

Patients with de novo bronchiectasis had significantly higher cough score (4.93 ± 0.27 vs. 3.05 ± 1.88; p < 0.001), higher frequency of colored sputum (72.7% vs. 18.8%; p < 0.001) and higher mMRC dyspnea score in comparison to those without bronchiectasis. Moreover, patients with de novo bronchiectasis had significantly higher frequency of respiratory distress (50% vs. 14%; p < 0.001) and respiratory failure (78.6% vs. 49.5%; p = 0.02) than those without bronchiectasis, respectively (Table 2).

Serum ferritin was significantly higher among those with De novo bronchiectasis in comparison to those without bronchiectasis (1392.97 ± 969.32 vs 489.74 ± 222.34; p < 0.001). In contrast, oxygen saturation at admission was significantly lower among those with de novo bronchiectasis in comparison to those without bronchiectasis (62.29 ± 15.67 vs. 84.38 ± 14.10; p < 0.001) (Table 3).

Fig. 1 Flowchart of screened COVID-19 cases included in the study (n = 425)
Regarding the course of COVID-19 infection among both groups, the frequency of ICU’s admission (64.3% vs. 25.3%; \( p = 0.02 \)), need to non-invasive (50% vs. 20.3%; \( p = 0.01 \)), and invasive mechanical ventilation (50% vs. 12.8%; \( p < 0.001 \)), duration of mechanical ventilation, ICU’s stay, and overall hospital stay were all statistically significantly higher among those with de novo bronchiectasis than those without bronchiectasis (\( p < 0.001 \)). As regards the outcome, death rate was also statistically significantly higher among those with de novo bronchiectasis (14.8% vs. 35.7%; \( p = 0.04 \)) (Table 4).

Table 1 Demographic characteristics of COVID-19 patients without and with de novo bronchiectasis included in the study

|                        | COVID-19 without bronchiectasis (n = 400) | COVID-19 with de novo bronchiectasis (n = 14) | \( p \) |
|------------------------|------------------------------------------|---------------------------------------------|------|
| Age (years)            | 52.62 ± 17.80                            | 57.64 ± 10.96                              | 0.30 |
| Sex                    |                                          |                                             | 0.45 |
| Male                   | 257 (64.3%)                              | 10 (71.4%)                                 |      |
| Female                 | 143 (35.8%)                              | 4 (28.6%)                                  |      |
| Active smoking         | 323 (80.8%)                              | 5 (35.7%)                                  | < 0.001 |
| Comorbidities          |                                          |                                             |      |
| COPD                   | 26 (6.5%)                                | 6 (42.9%)                                  | < 0.001 |
| Bronchial asthma       | 5 (1.3%)                                 | 0                                           | 0.84 |
| Diabetes mellitus      | 76 (19%)                                 | 2 (14.3%)                                  | 0.49 |
| Hypertension           | 106 (26.5%)                              | 1 (7.1%)                                   | 0.08 |
| Hepatic disease        | 2 (0.5%)                                 | 0                                           | 0.93 |
| Renal disease          | 14 (3.5%)                                | 0                                           | 0.61 |
| Cardiac diseases       | 29 (7.2%)                                | 1 (7.1%)                                   | 0.37 |
| Other                  | 28 (7%)                                  | 3 (21.4%)                                  | 0.07 |

Table 2 Clinical characteristics of COVID-19 patients without and with de novo bronchiectasis included in the study

|                        | COVID-19 without bronchiectasis (n = 400) | COVID-19 with de novo bronchiectasis (n = 14) | \( p \) |
|------------------------|------------------------------------------|---------------------------------------------|------|
| Cough                  | 338 (84.5%)                              | 14 (100%)                                  | 0.33 |
| Cough score            | 3.05 ± 1.88                              | 4.93 ± 0.27                                | < 0.001 |
| Sputum                 |                                          |                                             | < 0.001 |
| None                   | 309 (77.3%)                              | 2 (14.3%)                                  |      |
| Whitish                | 16 (4%)                                  | 1 (1.7%)                                   |      |
| Colored                | 75 (18.8%)                               | 11 (72.7%)                                 |      |
| Blood tinged           | 0                                        | 0                                           |      |
| Dyspnea                | 294 (73.5%)                              | 13 (92.9%)                                 | 0.08 |
| mMRC score             |                                          |                                             | 0.04 |
| 0                      | 137 (34.3%)                              | 1 (7.1%)                                   |      |
| 1                      | 5 (1.3%)                                 | 0                                           |      |
| 2                      | 53 (13.3%)                               | 0                                           |      |
| 3                      | 4 (1%)                                   | 0                                           |      |
| 4                      | 201 (50.2%)                              | 13 (92.9%)                                 |      |
| Fatigue                | 393 (98.3%)                              | 14 (100%)                                  | 0.78 |
| Sore throat            | 123 (30.8%)                              | 3 (21.4%)                                  | 0.33 |
| Cyanosis               | 199 (49.8%)                              | 10 (71.4%)                                 | 0.09 |
| Respiratory distress   | 56 (14%)                                 | 7 (50%)                                    | < 0.001 |
| Respiratory failure    | 198 (49.5%)                              | 11 (78.6%)                                 | 0.02 |

Table 3 Laboratory findings of COVID-19 patients without and with de novo bronchiectasis included in the study

|                        | COVID-19 without bronchiectasis (n = 400) | COVID-19 with de novo bronchiectasis (n = 14) | \( p \) |
|------------------------|------------------------------------------|---------------------------------------------|------|
| Leucocytes (10^3/μl)   | 9.47 ± 4.01                              | 11.12 ± 5.32                               | 0.13 |
| Lymphocytes (10^3/μl)  | 1.18 ± 0.68                              | 0.86 ± 0.47                                | 0.09 |
| CRP (mg/dl)            | 51.64 ± 34.45                            | 72.38 ± 52.69                              | 0.21 |
| D-dimer (ng)           | 1.45 ± 1.22                              | 1.93 ± 0.93                                | 0.61 |
| Serum ferritin         | 489.7 ± 222.34                           | 1392.97 ± 969.32                          | < 0.001 |
| SO2 at admission (%)   | 84.38 ± 14.10                            | 62.29 ± 15.67                              | < 0.001 |
| SO2 at discharge (%)   | 88.78 ± 19.90                            | 93.88 ± 1.47                              | 0.53 |

Data expressed as frequency (percentage), mean (SD). \( p \) value was significant if \( p < 0.05 \)

mMRC modified medical research council, COVID-19 coronavirus disease 2019

Cough score was compared by Mann-Whitney test and all nominal data was compared by chi² test

Regard the course of COVID-19 infection among both groups, the frequency of ICU’s admission (64.3% vs. 25.3%; \( p = 0.02 \)), need to non-invasive (50% vs. 20.3%; \( p = 0.01 \)), and invasive mechanical ventilation (50% vs. 12.8%; \( p < 0.001 \)), duration of mechanical ventilation, ICU’s stay, and overall hospital stay were all statistically significantly higher among those with de novo bronchiectasis than those without bronchiectasis (\( p < 0.001 \)). As regards the outcome, death rate was also statistically significantly higher among those with de novo bronchiectasis (14.8% vs. 35.7%; \( p = 0.04 \)) (Table 4).
Discussion
This cross-sectional study included 425 patients with COVID-19 infection confirmed by PCR in duration between July 2021 and February 2022. Patients were subdivided into three groups according to the presence or absence of bronchiectasis, COVID19 patients without bronchiectasis (group I) (94.1%), COVID19 patients developing bronchiectasis (group II) (3.3%) and bronchiectasis patients with COVID19 (group III) (2.6%).

A Chinese nationwide retrospective cohort studied the prevalence of chronic respiratory diseases among 39,420 laboratory-confirmed COVID-19 patients and its outcome from the electronic medical records, found that bronchiectasis was present in 27.9%. The association between COPD and bronchiectasis was found in 50.7% while association asthma and bronchiectasis was found in 15.9% of those patients, respectively [12]. On the other hand, Ambrosetti and colleagues detected two cases of lower lung lobe bronchiectasis developed in a few days and confirmed by CT in two patients with severe respiratory symptoms due to COVID-19 infection without significant comorbidities [13].

Another retrospective study analyzed the radiological finding of 81 patients with COVID-19 detected bronchiectasis in nine (11%) out of all included patients. The incidence of bronchiectasis development was increased with disease progression according to that study [14].

Furthermore, out of 101 COVID-19 positive cases examined in Zhao and colleagues’ retrospective study 53 patients (52.5%) had traction bronchiectasis, similar to that seen post SARS [15].

By comparing 8070 patients with a confirmed diagnosis of COVID-19 after January 2020 with the matched 121,050 age-, sex-, and residence non COVID participants registered in the Korean National Health Insurance Service (NHIS), the rate of bronchiectasis was 1.6% in the COVID-19 group and 1.4% in the matched group (p = 0.003) with a 1.22-fold increased odds ratio of the prevalence of bronchiectasis in the COVID-19 group relative to the matched group [16].

Another 6 months longitudinal study among 114 survivors after severe pneumonic type COVID-19 infection revealed a radiological evidence of bronchiectasis development in up to 24% of the patients at the follow up 6 months period compared with only 7% in the acute stage of the disease. These findings suggest that bronchiectasis (at least from a radiological point of view) can appear in up to a quarter of patients who suffered from severe COVID-19 pneumonia [17]. Moreover, Hanley et al. observed that most patients presented with bronchiectasis also had pulmonary fibrotic changes secondary to the COVID-19 pneumonia [17]. In this respect, the nature of the inflammatory component of this bronchiectasis, its potential to lead to recurrent bronchial infection and inflammation by potentially pathogenic microorganisms and, therefore, its potential to worsen prognosis, are unknown [19].

In regard to the demographic data of patients included in the current study, patients with de novo bronchiectasis had significantly higher frequency of COPD in comparison to those without bronchiectasis. All other comparisons including age, sex, and other comorbidities such as hypertension, diabetes mellitus, renal, and cardiac diseases were statistically insignificant. In a previous large series, COVID-19 patients with bronchiectasis were significantly older with more frequent pulmonary comorbidities, such as asthma (62.1% versus 30.4%) and COPD (57.6% versus

| Table 4 Clinical course and outcome of COVID-19 patients without and with de novo bronchiectasis included in the study |
|-------------------------------------------------------------|
| **COVID-19 without bronchiectasis (n = 400)** | **COVID-19 with de novo bronchiectasis (n = 14)** | **P** |
| Management site | | < 0.001 |
| At home 195 (48.8%) | 3 (21.4%) | 0.51 |
| At the ward 104 (26%) | 2 (14.3%) | 0.61 |
| ICU 101 (25.3%) | 9 (64.3%) | 0.01 |
| Hospital stay (day) 4.33 ± 2.15 | 25.14 ± 10.98 | < 0.001 |
| ICU’s stay (day) 1.79 ± 1.32 | 11.07 ± 10.45 | < 0.001 |
| Ventilatory support | | |
| NRM 73 (18.3%) | 2 (14.3%) | 0.51 |
| Vapotherm 25 (6.3%) | 1 (7.1%) | 0.61 |
| Non-invasive ventilation 81 (20.3%) | 7 (50%) | 0.01 |
| Mechanical ventilation 51 (12.8%) | 7 (50%) | < 0.001 |
| Duration of MV (day) 3.57 ± 1.23 | 14.13 ± 7.57 | < 0.001 |
| Outcome | | 0.04 |
| Alive 341 (85.3%) | 9 (64.3%) | 0.04 |
| Death 59 (14.8%) | 5 (35.7%) | 0.04 |

Data expressed as frequency (percentage), mean (SD). P value was significant if < 0.05. ICU intensive care unit, NRM non-rebreathing mask, MV mechanical ventilation, COVID-19 coronavirus disease 2019

Continuous data was compared Mann-Whitney test and all nominal data was compared by ch2 test.
Patients with de novo bronchiectasis had significantly higher cough score and frequency of colored sputum production in comparison to those without bronchiectasis in the current study which could be explained by the pathological nature of bronchiectasis as a suppurative disease characterized by chronic cough and sputum production due to impaired mucociliary clearance [20].

Also, patients with de novo bronchiectasis had significantly higher frequency of respiratory failure and lower oxygen saturation at time of admission in comparison to those without bronchiectasis in the current study. Hypoxemia may be developed in those groups due to fibrotic changes which lead to traction bronchiectasis or due to chronic obstructive lung disease which affect lung function [21, 22].

There was also significant elevated serum ferritin level among those with de novo bronchiectasis in comparison to those without bronchiectasis. This result can be explained by ferritin contribution to increased production of free radicals and hence oxidative tissue damage. Ferritin level is concomitant with both acute and chronic inflammatory processes. Thus, elevated ferritin that reflects persistent inflammatory reactions that can cause structural damage of the pulmonary parenchyma 2ry to COVID-19 infection [23].

The frequency of ICU's admission, need to non-invasive and invasive mechanical ventilation, duration of mechanical ventilation, ICU's stay, and overall hospital stay were all statistically significantly higher among those with De novo bronchiectasis than those without bronchiectasis in the current study. Two cases of COVID associated bronchiectasis in Ambrosetti et al. study presented by respiratory failure, elevation of CRP and D-dimer, and need ICU admission for non-rebreathing mask or non-invasive ventilation [5]. Han et al. also observed that the median hospital stay was longer for COVID-19 participants who developed bronchiectasis than those who did not (27 days [IQR, 26] vs 15 days [IQR, 8], P 0.001) [17]. Moreover, Suliman and colleagues reported a patient who developed progressive bronchiectasis 4 weeks after the onset of severe COVID-19 pneumonia. This patient needed ICU admission for invasive ventilation with long hospital stay (39 days) and long duration of PCR conversion as well [24].

Choi et al. observed that COVID-19 patients with bronchiectasis suffered from more severe infection than those without bronchiectasis. In that study, COVID-19 patients with bronchiectasis had worse course and outcome regarding use of supplemental oxygen, ICU admission rates, need for ECMO, and higher mortality than those without bronchiectasis. Impaired mucociliary clearance and chronic inflammation in the airway of patients with bronchiectasis is likely to increase their susceptibility to and severity of COVID-19 [16].

Regarding the outcome, the current study revealed that death rate was significantly higher among those with de novo bronchiectasis than those without bronchiectasis.

To our knowledge, no previous studies had discussed the risk factors for bronchiectasis development in COVID-19 infection but advanced age, smoking, sever COVID-19 infection, high levels of inflammatory biomarkers and prolonged mechanical ventilation are reported risk factors for development of post-COVID-19 pulmonary fibrosis [25, 26].

The current study faced some limitations. First, the small number of recruited patients in a single city during a limited time frame resulted in a small number of patients who developed bronchiectasis. Thus, the accuracy of comparative statistics could not be fully guaranteed. Second, we evaluated the development of bronchiectasis in the acute stage of COVID-19 infection (4 weeks), however, the development of traction bronchiectasis in post-COVID19 fibrosis was not assessed. Third, the impact of different and widely variable antimicrobial, anti-inflammatory, and immunosuppressive drugs used in the treatment of COVID-19 infection on development and progression bronchiectasis was not evaluated.

In conclusion, bronchiectasis is an uncommon presentation among COVID-19 patients. However, bronchiectasis increases disease burden in COVID-19 patients. It may have a negative impact on the outcome. Awareness must be raised among physicians and radiologists about bronchiectasis as an atypical presentation for COVID-19 infection. Moreover, bronchiectasis could be a possible common sequel for COVID infection. Thus, screening of bronchiectasis in survivors of COVID-19 infection especially those with chronic pulmonary symptoms or recurrent respiratory tract infection should be recommended.

**Abbreviations**
COVID-19: Corona Virus Disease 2019; ECMO: Extra-corporeal membrane oxygenation; GGO: Ground glass opacity; HRCT: High-resolution computed tomography; mMRC: Modified Medical Research Council; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2.

**Acknowledgements**
None.
Authors’ contributions
AARMH: conception, design, and revision. AMS: statistical analysis and medical writing. MKH: statistical analysis and medical writing. MAC: data collection and medical writing. All authors read and approved the final manuscript.

Funding
No financial support was required.

Availability of data and materials
The datasets analyzed during the current study are available upon request.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the Assiut University, Faculty of Medicine ethical committee (IRB no.17101456). The signed informed consent form was a permanent part of the participants study records, and it was maintained in the same manner as other records. It was conducted in accordance with the provisions of the Declaration of Helsinki. The study was also registered in clinicaltrials.gov under number (NCT04910113).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Chest Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
2Assiut Police Hospital, Assiut, Egypt.

Received: 10 July 2022   Accepted: 1 November 2022
Published online: 18 November 2022

References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395(10223):497–506
2. WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https://covid19.who.int/ (last cited: 18 April 2022).
3. Chung M, Bernheim A, Mei X, Zhang N, Huang M, Zeng X et al (2020) CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 295(1):202–207
4. Kanne JP, Bai H, Bernheim A, Chung M, Haramati LB, Kallmes DF et al (2021) COVID-19 Imaging: what we know now and what remains unknown. Radiology. 299(3):E262–EE79
5. Ambrosetti MC, Battocchio G, Zamboni GA, Fava C, Tacconelli E, Manueto G (2020) Rapid onset of bronchiectasis in COVID-19 pneumonia: two cases studied with CT. Radiol Case Rep. 15(11):2098–2103
6. José RJ, Manuel A, Gibson-Bailey K, Lee L (2020) Post COVID-19 bronchiectasis: a potential epidemic within a pandemic. Expert Rev Respir Med. 14(12):1183–1184
7. World Health O. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. Geneva: World Health Organization, 2020 2020. Contract No: WHO/2019-nCoV/Clinical/2020.4.
8. Masoud H, Elssal G, Hassany M, Shawkly A, Abdel Hakim M, Zaky S (2021) Management protocol for COVID-19 patients MoHP protocol for COVID19 November 2020.
9. Hsu JY, Stone RA, Logan-Sinclair RB, Worsdell M, Busst CM, Chung KF (1994) Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J. 7(7):1246–1253
10. Mohamed IA, Hasan HA, Abdel-Tawab M (2021) CT characteristics and laboratory findings of COVID-19 pneumonia in relation to patient outcome. Egyptian Journal of Radiology and Nuclear Medicine. 52(1):28
11. King PT (2009) The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 4:411–419
12. Guan W-J, Liang W-H, Shi Y, Gan L-X, Wang H-B, He J-X et al (2021) Chronic respiratory diseases and the outcomes of COVID-19: a nationwide retrospective cohort study of 39,420 cases. J Allergy Clin Immunol Pract. 9(7):2645–55.e14
13. Ambrosetti MC, Battocchio G, Zamboni GA, Fava C, Tacconelli E, Manueto G (2020) Rapid onset of bronchiectasis in COVID-19 Pneumonia: two cases studied with CT. Radiol Case Rep. 15(11):2098–2103
14. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J et al (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious diseases. 20(4):425–434
15. Zhao W, Zhong Z, Xie X, Yu Q, Liu J (2020) Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol. 214(5):1072–1077
16. Choi H, Lee H, Lee SK, Yang B, Chung SJ, Yeo Y et al (2021) Impact of bronchiectasis on susceptibility to and severity of COVID-19: a nationwide cohort study. Ther Adv Respir Dis. 15:1753466621995043
17. Han X, Fan Y, Alwalid O, Li N, Jia X, Yuan M et al (2021) Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 299(1):E177–Ee86
18. Hanley B, Lucas SB, Youd E, Swift B, Osborn M (2020) Autopsy in suspected COVID-19 cases. J Clin Pathol. 73(5):239–242
19. Martinez-Garcia MA, Aksamit TR, Aliberti S (2021) Bronchiectasis as a long-term consequence of SARS-COVID-19 pneumonia: future studies are needed. Arch Bronconeumol. 57(12):739–740
20. Chalmers JD, Chang AB, Chotirmall SH, Dhar R, McShane PJ (2018) Bronchiectasis. Nature Reviews Disease Primers. 4(1):45
21. Koulouris NG, Retsou S, Kosmas E, Dimakou K, Malagari K, Mantzikopoulos G et al (2003) Tidal expiratory flow limitation, dyspnoea and exercise capacity in patients with bilateral bronchiectasis. Eur Respir J. 21(5):743–748
22. Roberts HR, Wells AU, Milne DG, Rubens MB, Kolbe J, Cole PJ et al (2000) Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax. 55(3):198–204
23. Kim J, Wessling-Resnick M. The Role of Iron Metabolism in Lung Inflammation and Injury. J Allergy Ther. 2012;3(Suppl 4):004. https://doi.org/10.4172/2155-6191.1000.4. Pub 2012 Jan 25
24. Suliman AM, Bitar BW, Fartoog QA, Elarabi AM, Aboukamar MR, Abdulhadi AS (2021) COVID-19-Associated Bronchiectasis and Its Impact on Prognosis. Cureus. 13(5):e15051
25. Ojo AS, Balogun SA, Williams OT, Ojo OS (2020) Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulmonary Medicine. 2020:6175964
26. Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H (2020) Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 21(6):746–755

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:
► Convenient online submission
► Rigorous peer review
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com